Management and Pathophysiology of Functional Gastrointestinal Disorders

Shin Fukudo\textsuperscript{a}  Hiroyuki Kuwano\textsuperscript{b}  Hiroto Miwa\textsuperscript{c}

\textsuperscript{a}Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Miyagi, 
\textsuperscript{b}Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, and 
\textsuperscript{c}Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

\textbf{Key Words}
Functional dyspepsia  
Functional gastrointestinal disorder  
5-Hydroxytryptamine  
Pathophysiology  
Pharmacotherapy  
Postprandial distress syndrome  
Transient receptor potential vanilloid-1  
Transient receptor potential A1  
Chronic intestinal pseudo-obstruction

\textbf{Abstract}
Since 2005, every annual meeting of the Japanese Gastroenterological Association has included a core symposium for functional gastrointestinal disorders. At the 6th annual meeting, the core symposium was ‘Pathophysiology and New Treatment’. At the 7th annual meeting, the core symposium was ‘Pathophysiology and Motility’. This review summarizes the papers presented at these meetings. At the 6th meeting, we recognized that Japanese researchers successfully produced and developed many agents that are safe and effective for the treatment of functional gastrointestinal disorders, such as 5-hydroxytryptamine receptor-associated compounds, lubiprostone, Japanese herbal medicine, and other drugs. Data were validated from a clinical as well as an experimental viewpoint. Findings included the effects of sumatriptan and nizatidine, acylated or des-acylated ghrelin, T-cell-activating anti-CD3 antibody, and transient receptor potential vanilloid-1. At the 7th meeting, not only functional dyspepsia and irritable bowel syndrome (IBS), but also non-erosive esophageal reflux disease (NERD) and chronic intestinal pseudo-obstruction were actively discussed from a motility viewpoint, including papers about sham feeding and gastric motility, genetic polymorphism and motility, the role of transient receptor potential A1 on gastric accommodation, esophageal motility and NERD, diagnosis and treatment of chronic intestinal pseudo-obstruction, immunological basis of motility in IBS, developing non-invasive colonic function test, and fecal distribution in IBS patients.

Copyright © 2012 S. Karger AG, Basel

\textbf{Introduction}

The field of the science of digestion is greatly expanding. Traditionally, digestive diseases were considered to be limited to the gastrointestinal (GI) tract, the hepatobiliary system, and the pancreas. Although the pathophysiological condition of digestive disease in the digestive organs is primarily important, significance of regulatory factors on and impact on the other systems from the digestive organs is gradually increasing in the society. Functional GI disorders (FGIDs) are the typical examples of how the digestive system plays a crucial role in the normal lives of humans regardless of their living area.

\textbf{Pathophysiology and New Treatment}

The 6th annual meeting of the Japanese Gastroenterological Association (February 2010 in Fukuoka, organized by Mitsuo Iida, Kyushu University) was chaired by Shin Fukudo (Tohoku University) and Hiroto Miwa (Hyogo...
College of Medicine). The theme of the core symposium was ‘Pathophysiology and New Treatment’ and eight active researchers presented findings. Nakada et al. [1] reported that a significant difference in reduction of symptom scores between mosapride (5-hydroxytryptamine, 5-HT₄ receptor agonist) and teprenon was found in 618 dyspeptic patients in the Japan Mosapride Mega-Study. The responder rate to mosapride was superior to that of teprenon. Tomita et al. [2] described a cross-over trial of gastric emptying using ⁹⁹ᵐTc-Sn-colloid scintigram that compared placebo, sumatriptan, and mosapride in 10 healthy subjects. Sumatriptan increased reservoir function and gastric emptying. Mosapride increased both reservoir function and gastric emptying.

Futagami et al. [3] showed that administration of the histamine-2 receptor antagonist nizatidine significantly improved both gastric emptying and clinical symptoms in functional dyspepsia (FD) patients with impaired gastric emptying. Neither acylated nor des-acylated ghrelin levels in plasma were changed in FD patients treated with nizatidine compared with those treated with placebo. Another report [4] showed that acylated ghrelin levels were significantly lower in non-erosive esophageal reflux disease (NERD) and postprandial distress syndrome (PDS) patients than in healthy volunteers. Tominaga et al. [5] reported that disordered emptying was seen in 55.7% (34/61) of FD patients. Among them, delay was seen in 67.6% (23/34) and acceleration was detected in 32.4% (11/34). Impaired reservoir function was found in 49.2% (30/61) of patients, which was significantly associated with delayed and disordered (delay + acceleration) emptying. Symptoms in the motility disordered group tended to be more severe than in the normal group. They also use positron emission tomography with [¹¹C]N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine [6]. In their report, FD patients showed higher binding potential of the 5-HT transporter in the thalamus and the midbrain than controls.

Mizukami et al. [7] tried to evaluate bowel motility and morphology in 146 patients with irritable bowel syndrome (IBS) by colonoscopy with the collapse-submergence (water navigation) method. In their observation, peristalsis persisted for 8 min or more in 67% of male patients with IBS with diarrhea (IBS-D) and 78% of female patients with IBS-D; segmental type motility occurred in 48% of male patients with IBS with constipation (IBS-C) and 10% of female patients with IBS-C after administration of an antispasmodic. Onodera et al. [8] examined the association of β₃-adrenoceptor and cholinergic receptor muscarinic-3 (CHRM3) polymorphisms with IBS. The β₃-adrenoceptor genotype frequencies of T/C in IBS patients were significantly higher compared with those in controls. The frequencies of the CHRM3 genotypes were significantly different between IBS patients with more than 3 years’ disease duration and those with less than 3 years’ disease duration.

Akiho and Nakamura [9] evaluated the effects of daikenchuto (DKT), a pharmaceutical-grade Japanese herbal medicine, on the hypercontractility of intestinal smooth muscle persisting after acute inflammation induced by a T-cell-activating anti-CD3 antibody (αCD3). DKT ameliorated the αCD3-induced muscle hypercontractility in both the muscle strips and smooth muscle cells (fig. 1). Although the influence of DKT on mRNA expressions was moderate, the protein expressions of interleukin (IL)-13 and IL-17 were significantly decreased. The observed modulation of cytokine expression and function by DKT may lead to the development of new pharmacotherapeutic strategies aimed at a wide variety of gut motor dysfunction disorders. Matsumoto et al. [10] found transient receptor potential vanilloid-1 (TRPV1) immunoreactivity in the mucosa, submucosal, and muscle layers and myenteric plexus in the rectum and distal colon. In contrast, TRPV1-positive axons were sparsely distributed in the transverse and proximal colon. Capsaicin induced a fast transient contraction, followed by a large long-lasting contraction in the rectum and distal colon. These authors also reported colocalization of immunoreactivity of TRPV1 and calcitonin gene-related peptide, substance P, and neuronal nitric oxide synthase in the colorectum, suggesting regulation of colorectal function by TRPV1-expressing nerve cells (fig. 2) [11].

**Fig. 1.** Effect of DKT on αCD3-induced hypercontractility of murine smooth muscle cells (SMC). Photomicrographs of SMC isolated from the small intestine of αCD3-injected mice with or without DKT. The contraction was induced by addition of 10⁻¹¹ M carbamylcholine chloride (CCh) [from 9, with permission].
Pathophysiology and Gastrointestinal Motility

At the 7th annual meeting (February 2011 in Kyoto, organized by Toshikazu Yoshikawa, Kyoto Prefectural University of Medicine), the title of the core symposium was ‘Functional Gastrointestinal Disorders (FGID); Pathophysiology and Motility’. This meeting was chaired by Hiroyuki Kuwano (Gumma University) and Hiroto Miwa. At this meeting, ten researchers presented their papers at the symposium. Ohno et al. outlined basic GI motility and ways in which it can be evaluated. Choosing an appropriate evaluation method and proper interpretation are essential. Manabe et al. [12] reported results of a prospective study of the gastric response to modified sham feeding in patients with PDS. First, cardiovascular autonomic function was assessed by spectral analysis of...
RR interval variability. Antral contraction was then evaluated by ultrasonography after modified sham feeding was performed to stimulate the cephalic phase of vagal activity. Autonomic abnormalities affecting the cephalic phase of vagal activity may be important in the pathogenesis of FD. Shibata et al. presented the correlation between 5-HT, brain-derived neurotrophic factor, ghrelin, neuropeptide Y, and T1R3 gene polymorphism and dyspeptic symptoms in a Japanese population. They suggested that the 5-HT1a receptor polymorphism is associated with the appearance of FD. The role of genetics in the development of dyspepsia needs further evaluation.

Kondo et al. [13] presented the role of transient receptor potential A1 (TRPA1) in gastric adaptive relaxation. They developed a new gastric pressure measurement model that can be performed while subjects are awake using a guinea pig, and enabled the measurement of gastric adaptive relaxation under physiological conditions. TRPA1 raised the intragastric pressure via the cholinergic pathway and negatively controlled adaptive relaxation. Iwakiri et al. [14] presented the characteristics of symptomatic reflux episodes in patients with NERD who have a positive symptom index while receiving proton pump inhibitor therapy. Proximal reflux is more likely to be associated with reflux symptoms, irrespective of the acidity of the refluxate or the duration of proximal reflux episodes. In NERD patients who have a positive symptom index on double-dose proton pump inhibitor therapy, the high proximal extent of refluxate is a major factor associated with reflux perception. The lack of secondary peristalsis may be related to the rise of proximal reflux. Funaki et al. reported that functional heartburn was defined in Rome III in 2006; however, there were difficulties in diagnosing all functional heartburn based on this definition. They evaluated esophageal function and pointed out that many esophageal physiologic dysfunctions were included in the diagnosis of functional heartburn based on the definition of Rome III, and determined that it is necessary to define functional heartburn in a more narrow sense to make an appropriate diagnosis.

Sakamoto et al. reported on the current state of diagnosis and treatment of chronic intestinal pseudo-obstruction, based on the result of the survey of the research group of the Ministry of Health, Labor and Welfare. They indicated that further research and surveys conducted by medical institutions nationwide, including surgery facilities, would be needed to determine the etiology of chronic intestinal pseudo-obstruction and rapid establishment of diagnostic standards and treatments. Akiho et al. [15] showed that understanding the underlying immunological basis of the altered GI motor dysfunction in IBS by considering the role of the Th1/Th2 balance or Th17 cytokines may ultimately lead to new therapeutic strategies for IBS. Okahisa et al. established a simple and non-invasive evaluation method of assessing colonic function by measuring electric potential. They reported that this method is useful for the evaluation of various medicines under development, as well as the diagnosis, detailed classification, and treatment of the FGID. Kusunoki et al. [16] examined fecal distribution in the colon in uninfected IBS and post-infectious IBS patients using ultrasonography. They showed that early onset post-infectious IBS and mental instability such as depression and anxiety were major risk factors. They also suggested the possibility that the strength of the inflammation of long-term IBS could be a risk factor as well.

**Perspective of FGID Research**

In these sessions, pathophysiology of FGID was discussed by front-line Japanese researchers in this field. Considering that the mainstream of GI research has been focused on morphological studies, presentation of such high-quality and unique papers encourages us to further perform more research in this field. Increased understanding of pathophysiology of FGID will facilitate drug discovery. It was noted that Japanese researchers successfully produced and developed many agents that are safe and effective for FGID. They are ramosetron for IBS-D [17], lubiprostone for chronic idiopathic constipation, and IBS-C [18], tandospirone for FD [19], and acotiamide for FD [20]. Besides, several Japanese agents for FGIDs are available in Asia. Mosapride is available as a 5-HT4 receptor agonist for clinical use. This agent is predominantly prescribed for patients with FD, but a recent study clarified its stimulatory effect on the colorectum in patients with IBS [21]. Further data on clinical trials of new agents for FGID from Japan and the other Asian countries are warranted.

**Direction of Research in the Future**

Like researches listed in this article, basic and clinical investigations are indispensable for care and cure for FGIDs. Regarding the era of genome-wide association studies, nature or nurture problems of FGIDs will be solved scientifically in the future. Common genes and common risk stimuli for FGIDs regardless of the ethnic factors and/or cultural issues may be present. In addition,
some different features of FGIDs, some differences in genes, and differences in cultural behaviors including the dietary factors/gut microbiota in the different countries will provide us important keys to open the black box of FGIDs. The theme of the next core symposium at the 8th JGA meeting in 2012 will be 'Functional Gastrointestinal Disorders (FGID): Pathophysiology and Sensation'.

Conclusion

Molecular mechanism and whole-body analyses for FGIDs are actively and continuously studied in Japan. Further research and development of treatment for FGID are warranted.

References


Acknowledgements

This research was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Health, Welfare, and Labor of Japan.

Disclosure Statement

The authors declare that there is no conflict of interest in relation to the contents of this article.